ArticleFrontiers in immunology2017

HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.

Amy K Erbe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.